Q4 2025 · 13F-HR
Remedium Capital Partners, LLCholdings as filed
Filed 2026-02-12 · accession 0002104501-26-000004
$170,211
Reported value
6
Positions
2025-12-31
Period end
The Brief · Remedium Capital Partners, LLC · Q4 2025
AI · grounded in 13F
Remedium Capital Partners, LLC established six new positions to reach a total AUM of $170,211. The fund's largest move was a new position in Spyre Therapeutics Inc SYRE valued at $47,706. Other new entries include Oruka Therapeutics Inc ORKA at $47,054 and Apogee Therapeutics Inc APGE at $44,050.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00773J202 | SYRE | Spyre Therapeutics Inc | $47,706 | 28.0% | 1,456,231 | Common | SOLE |
| 687604108 | ORKA | Oruka Therapeutics Inc | $47,054 | 27.6% | 1,552,414 | Common | SOLE |
| 03770N101 | APGE | Apogee Therapeutics Inc | $44,050 | 25.9% | 583,591 | Common | SOLE |
| 008064206 | JBIO | Jade Biosciences Inc | $24,345 | 14.3% | 1,577,750 | Common | SOLE |
| 38000Q201 | — | Crescent Biopharma Inc | $4,284 | 2.52% | 361,250 | Common | SOLE |
| 36322Q206 | DMRA | Galecto Inc | $2,772 | 1.63% | 120,473 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.